Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice

Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocop...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheinberg, Morton, Castañeda-Hernández, Gilberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336503/
https://www.ncbi.nlm.nih.gov/pubmed/25677586
http://dx.doi.org/10.1186/s13075-014-0501-5
_version_ 1782358480508682240
author Scheinberg, Morton
Castañeda-Hernández, Gilberto
author_facet Scheinberg, Morton
Castañeda-Hernández, Gilberto
author_sort Scheinberg, Morton
collection PubMed
description Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology.
format Online
Article
Text
id pubmed-4336503
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43365032015-02-22 Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice Scheinberg, Morton Castañeda-Hernández, Gilberto Arthritis Res Ther Commentary Biosimilars that were not compared in clinical trials with the compound innovator are not true biosimilars (biocopies) and are associated with risks that the clinical rheumatologist should be aware of before generalized use. This article comments on various aspects surrounding the use of such biocopies in clinical rheumatology. BioMed Central 2014-12-06 2014 /pmc/articles/PMC4336503/ /pubmed/25677586 http://dx.doi.org/10.1186/s13075-014-0501-5 Text en © Scheinberg and Castañeda-Hernández; licensee BioMed Central Ltd. 2014 The licensee has exclusive rights to distribute this article, in any medium, for 6 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Scheinberg, Morton
Castañeda-Hernández, Gilberto
Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
title Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
title_full Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
title_fullStr Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
title_full_unstemmed Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
title_short Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
title_sort anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4336503/
https://www.ncbi.nlm.nih.gov/pubmed/25677586
http://dx.doi.org/10.1186/s13075-014-0501-5
work_keys_str_mv AT scheinbergmorton antitumornecrosisfactorpatentexpirationandtherisksofbiocopiesinclinicalpractice
AT castanedahernandezgilberto antitumornecrosisfactorpatentexpirationandtherisksofbiocopiesinclinicalpractice

Ejemplares similares